SCIENCE
Stopping Ozempic may raise heart attack and stroke risk
ScienceDailyMonday, September 21, 2026 at 1:35 PM
RedScroll Brief
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops.
RedScroll Signal
- Impact
- High
- Category
- Science
- Market relevance
- None
- Why it matters
- Scientific signal separates durable discovery from noise — and often foreshadows policy and product. A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops.
Why it matters
Scientific signal separates durable discovery from noise — and often foreshadows policy and product.
Background
ScienceDaily reported on this under science. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
ScienceDaily published: Stopping Ozempic may raise heart attack and stroke risk
Story is in today’s RedScroll edition. Follow the original source for updates.
More on
Related stories
- A global safety net for climate-risk intelligence is urgently needed
NatureSCIENCE
- Stem cells reverse stroke damage and restore movement in mice
ScienceDailySCIENCE
- Chronic stress may be quietly reshaping your heart
ScienceDailySCIENCE
- Biosecurity must protect human functional capacity
NatureSCIENCE
- Watch scientists decipher burnt scrolls without unrolling them
NatureSCIENCE
- Why insects need their own protected areas
NatureSCIENCE
Source
ScienceDaily
Original reporting by ScienceDaily. RedScroll provides an extractive briefing only.